Alimera Sciences Inc (ALIM) - Financial and Strategic SWOT Analysis Review

September 2021 | 52 pages | ID: AB58635E1DCEN
GlobalData

Abstracts

Alimera Sciences Inc (ALIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alimera Sciences Inc (Alimera) is a pharmaceutical company that discovers, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabetic macular edema (DME) in patients who have been previously treated with corticosteroids and did not show any clinically significant increase in intraocular pressure (IOP). Iluvien is also prescribed for treatment of recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS); proliferative diabetic retinopathy (NPDR); wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK, and others. Alimera is headquartered in Alpharetta, Georgia, the US.

Alimera Sciences Inc Key Recent Developments

Apr 28,2021: Alimera Sciences Announces First Quarter 2021 Financial Results
Apr 14,2021: Alimera Sciences Announces Second Quarter 2021 Financial Results
Apr 09,2021: Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
Mar 18,2021: Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
Mar 11,2021: Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Alimera Sciences Inc - Key Facts
Alimera Sciences Inc - Key Employees
Alimera Sciences Inc - Key Employee Biographies
Alimera Sciences Inc - Major Products and Services
Alimera Sciences Inc - History
Alimera Sciences Inc - Company Statement
Alimera Sciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Alimera Sciences Inc - Business Description
Geographical Segment: International
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Alimera Sciences Inc - Corporate Strategy
Alimera Sciences Inc - SWOT Analysis
SWOT Analysis - Overview
Alimera Sciences Inc - Strengths
Alimera Sciences Inc - Weaknesses
Alimera Sciences Inc - Opportunities
Alimera Sciences Inc - Threats
Alimera Sciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alimera Sciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 28, 2021: Alimera Sciences Announces First Quarter 2021 Financial Results
Apr 14, 2021: Alimera Sciences Announces Second Quarter 2021 Financial Results
Apr 09, 2021: Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
Mar 18, 2021: Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
Mar 11, 2021: Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
Mar 02, 2021: Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 24, 2021: Alimera Sciences reports fourth quarter and 2020 results
Feb 17, 2021: Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
Feb 15, 2021: Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
Jan 19, 2021: Alimera Sciences announces preliminary top-line results for fourth quarter and full-year 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Alimera Sciences Inc, Key Facts
Alimera Sciences Inc, Key Employees
Alimera Sciences Inc, Key Employee Biographies
Alimera Sciences Inc, Major Products and Services
Alimera Sciences Inc, History
Alimera Sciences Inc, Subsidiaries
Alimera Sciences Inc, Key Competitors
Alimera Sciences Inc, Ratios based on current share price
Alimera Sciences Inc, Annual Ratios
Alimera Sciences Inc, Annual Ratios (Cont...1)
Alimera Sciences Inc, Annual Ratios (Cont...2)
Alimera Sciences Inc, Interim Ratios
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alimera Sciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Alimera Sciences Inc, Performance Chart (2016 - 2020)
Alimera Sciences Inc, Ratio Charts
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021